Medscape www.medscape.com

References for:
Combination Therapy for Non-Hodgkin's Lymphoma: An Opportunity for Pharmaceutical Care in a Specialty Practice

[J Am Pharm Assoc 42(1):93-100, 2002. © 2002 American Pharmaceutical Association]

  1. Hepler CD. Pharmaceutical care and specialty practice. Pharmacotherapy. 1993;13:64S-69S.
  2. Hepler CD. Issues in implementing pharmaceutical care. Am J Hosp Pharm. 1993;50:1635-41.
  3. Strand LM, Cipolle RJ, Morley PC, Perrier DG. Levels of pharmaceutical care: a needs-based approach. Am J Hosp Pharm. 1991;48:547-50.
  4. Rhodes BA, Hladik Wb III, Norenberg JP. Clinical radiopharmacy: principles and practices. Semin Nucl Med. 1996;26:77-84.
  5. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-43.
  6. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
  7. Foon KA. Monoclonal antibodies in the treatment of lymphomas for the year 2000. Principles Pract Oncol. 2000;14:1-11.
  8. Kaminski M, Estes TGJ. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions [abstract]. Proc Am Soc Clin Oncol. 1998;17:A6.
  9. Kaminski M, Milik KZA, Francis CRL, Burgess J. Updated results of a phase I trial of 131-I-anti-B1 (anti-CD20) radioimmunotherapy (RIT) for refractory B-cell lymphoma. Blood. 1993;82:332a.
  10. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-65.
  11. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-81.
  12. Gates VL, Carey JE, Siegel JA, Kaminski MS, et al. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med. 1998;39:1230-6.
  13. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39:14S-20S.
  14. Kaminski M, Estes J. Iodine 131 tositumomab therapy for previously untreated follicular lymphoma. Proc Am Soc Clin Oncol. 2000;19:5A.
  15. Webster WB, Harwood SJ, Carroll RG, et al. Patient specific radioimmunotherapy of non-Hodgkin's lymphoma with 131I-anti B1 antibody: pharmacokinetic dosing. Pharmacotherapy. 2000;20:352.
  16. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-52.
  17. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-85.
  18. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992;52:6476-81.
  19. Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol. 1999;36:15-20.
  20. Farah RA, Clinchy B, Herrera L, Vitetta ES. The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr. 1998;8:321-56.
  21. Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med. 1998;39:1S.
  22. Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med. 1998;39:28S-33S.
  23. Zanzonico PB, Siegel JA, St. Germain J. A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. Health Phys. 2000;78:648-59.
  24. Sparks RB, Siegel JA, Wahl RL. The need for better methods to determine release criteria for patients administered radioactive material. Health Phys. 1998;75:385-8.
  25. Wahl RL, Azsadny KR, Estes P. Single center experience with iodine I131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL). J Nucl Med. 2000;41:309P.
  26. Gobar LS, Vose JM, Magnuson DE. Radioimmunotherapy with iodine 131 tositumomab: serious adverse events immediately after therapy in 51 patients. J Nucl Med. 2000;41:269P.
  27. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-66.
  28. Gobar LS, Rutar FJ, Vose JA, Augustine SC. Efficacy of patient release criteria and instructions for outpatient radioimmunotherapy of lymphoma with BEXXAR (131I-tositumomab). J Nucl Med. 2000;41 (suppl):269P.
  29. Rutar FJ, Augustine SC, Colcher DM, et al. Outpatient treatment with 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42:907-15.